Latest Content

Ovarian Cancer Treatment Side Effects Make for a Difficult Balancing Act

May 23rd 2025, 5:00pm

By Kelly Irvin

Article

I urge researchers to look into why side effects occur in cancer drugs and to find ways to mitigate them that doesn’t impact their efficacy.

GLP-1 Drugs Linked to Fewer Obesity-Related Cancers

May 23rd 2025, 3:00pm

By Ariana Pelosci

Article

GLP-1 drugs lowered rates of obesity-related cancers and death versus DPP-4s, with no increased cancer risk, study finds.

Breaking Down Treatment Variables in AYA Patients With Cancer

May 23rd 2025, 1:00pm

By Ryan Scott

Article

Dr. Andrew M. Evens discussed the importance of differentiating AYA cancers from other age groups, specifically focusing on lymphoma care.

Itovebi Triplet Combo Boosts Survival in HR+, HER2– Breast Cancer

May 22nd 2025, 9:00pm

By Caroline Seymour

Article

Itovebi plus Ibrance and Faslodex improved overall survival in patients with PIK3CA-mutant, HR+, HER2–, endocrine-resistant breast cancer versus placebo.

Zepzelca Plus Tecentriq Boosts Survival in First-Line ES-SCLC Care

May 22nd 2025, 9:00pm

By Kristi Rosa

Article

Among patients with ES-SCLC, first-line maintenance therapy with Zepzelca plus Tecentriq led to improvements in PFS and OS versus Tecentriq alone.

Expert Offers Surveillance, Lifestyle Guidance After CRC, Anal Cancer

May 22nd 2025, 7:00pm

By Dr Rebecca Rhee

Video

Avoiding smoking, eating a high-fiber diet and routine screenings are key to reducing the risk of recurrence in colorectal or anal cancer.

Contemplating AI Assistance as a Cancer Survivor

May 22nd 2025, 5:00pm

By Felicia Mitchell

Article

When I saw a study about using AI facial recognition in cancer decision-making headlines, I decided to try my own informal, non-scientific experiment.

FDA's ODAC Votes Against Targeted Therapies in Bladder and Prostate Cancer

May 22nd 2025, 4:29pm

By Ryan Scott

Article

The FDA’s ODAC has voted against the risk/benefit profile of two targeted therapies for the treatment of bladder and prostate cancer, respectively.

PMB-CT01 Therapy Induces Complete Remission in Follicular Lymphoma

May 22nd 2025, 3:00pm

By Spencer Feldman

Article

A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.

Intra-Arterial Paraplatin Shows No Hearing Loss in Retinoblastoma

May 22nd 2025, 1:00pm

By Spencer Feldman

Article

DPOAE testing showed no hearing loss in children with retinoblastoma treated with intra-arterial paraplatin, suggesting preserved cochlear function.

A Trailblazer in Oncology Nursing and Research

May 21st 2025, 9:00pm

By Erin Pierce, M.S.N., APRN, FNP-C

Article

Gayle S. Jameson, M.S.N, ACNP-BC, AOCN, is a trailblazer whose expertise and compassion have made a profound impact on oncology care.

Evolving Myelofibrosis Treatments Aims to Fill Unmet Needs

May 21st 2025, 8:18pm

By Ryan Scott

Article

JAK inhibitors ease symptoms in myelofibrosis, but only stem cell transplant offers a cure; newer drugs aim to fill unmet needs, especially for anemia.

Understanding the Evolution of Waldenström Macroglobulinemia Treatment

May 21st 2025, 7:00pm

By Dr. Shirley D'Sa

Video

Dr. Shirley D’Sa discusses how treatment strategies for WM have evolved over the course of her career.

When Others say Your Own Thoughts About Cancer Aloud

May 21st 2025, 5:00pm

By Karen Cohn

Article

I'm a follicular lymphoma survivor, and hearing others name the quiet, lasting changes of life after cancer made me feel seen and understood.

FDA’s ODAC Casts Votes on the Use of Certain Treatment Options in Cancer Care

May 21st 2025, 4:05pm

By Ryan Scott

Article

The FDA'S ODAC has casted their votes on the use of certain treatments in both the relapsed/refractory DLBCL and myeloma patient populations, respectively.